Supplementary Table 1. Recommended dosing criteria and contraindications for each NOAC (for the prevention of stroke and systemic embolism in patients with NVAF) that were applied in the study.

NOAC	Reduced dosing criteria	Contraindications
Apixaban[a] **standard or normal recommended daily dose = 10 mg**	2.5 mg taken orally twice daily in patients with NVAF and ≥ 2 of the following: • age ≥ 80 years • body weight ≤ 60 kg • serum creatinine ≥ 1.5 mg/dL (133 micromole/L). Or, severe renal impairment (CrCL 15–29 mL/min)	*Note*: In patients with CrCL < 15 ml/min or undergoing dialysis, there is no clinical experience therefore apixaban is not recommended.
Dabigatran[b] **standard or normal recommended daily dose = 300mg**	• age ≥ 80 years • concomitant use of verapamil Reduction for consideration when[d]: • patients between 75–80 years • patients with moderate renal impairment (CrCL 30–50 mL/min • patients with gastritis oesophagitis or gastrooesophagel reflux.	• Severe renal impairment (CrCL < 30ml/min) *Note*: Dabigatran is also not recommended in patients with hepatic impairment or liver disease
Rivaroxaban[c] **standard or normal recommended daily dose = 20mg**	In patients with moderate/severe renal impairment (CrCL 15–49 ml/min)	• Severe renal impairment (creatinine clearance < 15 ml/min)

Sources from which our modified criteria were obtained.

[a]Eliquis. Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed 7 September 2018.

[b]Pradaxa. Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf

[c]Xarelto. Pradaxa. Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf

[d]Patients meeting at least one of these criteria were considered eligible for dose reduction in our study.

CrCL, creatinine clearance; NVAF, non-valvular atrial fibrillation